Federal prosecutors in Philadelphia indicted five people, including two research scientists, on charges of stealing trade secrets about drugs to treat cancer and other diseases from British drug giant GlaxoSmithKline.

According to prosecutors, two scientists at a Glaxo research facility emailed and downloaded confidential data about a dozen or so company products to associates who planned to sell and market the trade secrets through a company they set up in China, called Renopharma.

Lawyers for the defendants declined to comment. In a statement, Glaxo said it had been cooperating with federal authorities and "we do not believe the breach has had any material impact" on the company's business or research and development activity. A spokeswoman said the company has one such antibody in early stages of development. Ed McAndrew, a partner at Ballard Spahr, represents GlaxoSmithKline in the matter.

Related Practice